Basel, Switzerland

Claudio Zambaldo

This inventor holds 1 USPTO granted patent and 4 published patent applications and 3 EPO patents. Top assignee: Hoffmann-La Roche Inc.. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Claudio Zambaldo. Retrieved from https://idiyas.com/inventor/claudio-zambaldo

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 1 

 

Average Co-Inventor Count = 1.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Claudio Zambaldo: Innovator in Medicinal Chemistry

Introduction

Claudio Zambaldo is a notable inventor based in Basel, Switzerland. He is currently associated with F. Hoffmann-La Roche AG, a leading global healthcare company. Although he has not yet been granted any patents, his contributions to medicinal chemistry are significant.

Latest Patent Applications

Claudio Zambaldo has been involved in several recent patent applications. One of his latest applications is for "Pyrido[1,2-a]pyrimidin-4-one derivatives." This invention relates to a compound of formula (I), wherein R-R and A-A are defined in the description and claims. The compound can be utilized as a medicament. Another application is for "New Thiazolopyrimidinone derivatives," which also pertains to a compound of formula (I) with similar definitions for R-R and A-A. This compound can likewise be used as a medicament.

Conclusion

Claudio Zambaldo is an emerging inventor in the field of medicinal chemistry, with promising applications that could lead to significant advancements in healthcare. His work at F. Hoffmann-La Roche AG highlights his commitment to innovation in the pharmaceutical industry.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…